Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Ancestry-dependent patterns of somatic mosaicism and clonal hematopoiesis mutations in over 125,000 individuals reveal distinct cancer associations.
Colin-Leitzinger C et al.
Human Genomics, 2025
Molecular analysis of the evolutionary history of endometrial and ovarian carcinoma in Lynch syndrome.
Kauppinen AK et al.
International Journal of Cancer, 2025
Somatic mutation and selection at population scale.
Lawson ARJ et al.
Nature, 2025
Distinct characteristics of lymphoid and myeloid clonal hematopoiesis in World Trade Center first responders.
Esai Selvan M et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Mechanism of D-type cyclin recognition by the AMBRA1 E3 ligase receptor.
Wang Y et al.
Science Advances, 2025
Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes.
Hiitola E et al.
Science Advances, 2025
F-box protein FBXO32 ubiquitinates and stabilizes D-type cyclins to drive cancer progression.
Li F et al.
Nature Communications, 2025
Stabilization of GTSE1 by cyclin D1-CDK4/6-mediated phosphorylation promotes cell proliferation with implications for cancer prognosis.
García-Vázquez N et al.
Elife, 2025
Peripheral blood somatic mosaicism and clonal hematopoiesis across ancestry backgrounds.
Colin-Leitzinger C et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Stabilization of GTSE1 by cyclin D1-CDK4/6-mediated phosphorylation promotes cell proliferation: relevance in cancer prognosis.
García-Vázquez N et al.
Biorxiv : the Preprint Server for Biology, 2025
D-type cyclins regulate DNA mismatch repair in the G1 and S phases of the cell cycle, maintaining genome stability.
Rona G et al.
Biorxiv : the Preprint Server for Biology, 2024
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21.
Bélanger F et al.
The Journal of Biological Chemistry, 2023
Cdk4 Regulates Glioblastoma Cell Invasion and Stemness and Is Target of a Notch Inhibitor Plus Resveratrol Combined Treatment.
Giordano F et al.
International Journal of Molecular Sciences, 2023
Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors.
Kim M et al.
Cancer Research and Treatment, 2023
Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis.
Rezaeian AH et al.
Advances in Protein Chemistry and Structural Biology, 2023
Regulation of Cyclin D1 Degradation by Ubiquitin-Specific Protease 27X Is Critical for Cancer Cell Proliferation and Tumor Growth.
Alam S et al.
Molecular Cancer Research : Mcr, 2022
Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with Pten loss.
Yoshida A et al.
Oncogene, 2022
AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity.
Maiani E et al.
Nature, 2021
The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D.
Chaikovsky AC et al.
Nature, 2021
Cyclin D degradation by E3 ligases in cancer progression and treatment.
Qie S et al.
Seminars in Cancer Biology, 2020
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH et al.
Journal for Immunotherapy of Cancer, 2020
The double dealing of cyclin D1.
Tchakarska G et al.
Cell Cycle (georgetown, Tex.), 2020
Cullin-RING E3 Ubiquitin Ligase 7 in Growth Control and Cancer.
Pan ZQ
Advances in Experimental Medicine and Biology, 2020
Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
Nassar AH et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.
Qie S et al.
Nature Communications, 2019
Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells.
Gennaro VJ et al.
Proceedings of the National Academy of Sciences of the United States of America, 2018
Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas.
Xu J et al.
Plos One, 2018
CDK4 protein is degraded by anaphase-promoting complex/cyclosome in mitosis and reaccumulates in early G1 phase to initiate a new cell cycle in HeLa cells.
Chen H et al.
The Journal of Biological Chemistry, 2017
Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.
Eisfeld AK et al.
Leukemia, 2017
CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.
Mohanty A et al.
Oncotarget, 2016
Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation.
Chalermrujinanant C et al.
Oncogene, 2016
Paradoxical roles of cyclin D1 in DNA stability.
Jirawatnotai S et al.
Dna Repair, 2016
Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape.
Liu F et al.
Nature Reviews. Cancer, 2016
PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers.
Li Y et al.
Cancer Discovery, 2015
DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome.
Najas S et al.
Ebiomedicine, 2015
Aberrant expression of cyclin D1 in cancer.
Inoue K et al.
Signal Transduction Insights, 2015
Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression.
Lee Y et al.
Nature, 2014